Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) reported results from the largest individual‑patient meta-analysis of its Prolaris Biopsy Test in localized prostate cancer. Across 14 studies and 8,478 patients, the combined clinical risk (CCR) score was significantly prognostic for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups and initial management strategies.
The RNA-based test analyzes biopsy gene expression plus clinical data to support decisions between active surveillance, definitive therapy, and treatment escalation. According to Myriad Genetics, Prolaris provides independent, additive prognostic information beyond tools such as Gleason score, CAPRA, and NCCN risk group, and now includes AI digital pathology features.
Myriad Genetics (NASDAQ: MYGN) expanded availability of its Precise MRD™ assay to patients with breast, colorectal and renal cancers, potentially impacting more than 6 million people in the U.S. Precise MRD is a whole‑genome, tumor‑informed ctDNA test used from neoadjuvant therapy through long‑term surveillance.
New results from the prospective MONITOR‑Breast study in Future Oncology evaluated 154 stage I–III breast cancer patients with 949 plasma samples. Findings included 93% baseline ctDNA detection, 100% specificity for predicting pathological complete response and 44% more at‑risk patients identified with longitudinal testing compared with a single post‑therapy timepoint.
Myriad Genetics (NASDAQ: MYGN) appointed Raj Jampa as chief technology officer effective June 1, 2026. He will lead technology strategy and execution, including expanding AI use to improve efficiency, digital foundations, and customer experience, supporting Myriad’s molecular diagnostics and precision medicine growth strategy.
Myriad Genetics (NASDAQ: MYGN) will showcase new data on its Precise MRD™ molecular residual disease assay at the 2026 ASCO Annual Meeting. Six posters, many from the MONSTAR-SCREEN-3 study, highlight ultra-sensitive ctDNA detection across multiple solid tumors and its prognostic value for recurrence and treatment response.
Myriad will also host an Industry Expert Theater session on May 31 introducing Precise MRD and will feature additional cancer tests and biopharma services at booth #25081, including MyRisk, Prolaris + AI, MyChoice CDx, MSK-ACCESS and MSK-IMPACT.
Myriad Genetics (NASDAQ: MYGN) will launch the Prolaris + AI Test at the end of May 2026, integrating Prolaris genomics with PATHOMIQ AI-powered digital pathology.
This first-of-its-kind prostate cancer biomarker combines clinical-pathological features, molecular scoring and AI to support active surveillance decisions and personalize surveillance intensity.
Myriad Genetics (NASDAQ: MYGN) partnered with actress Jackie Tohn to promote hereditary cancer testing using the MyRisk Hereditary Cancer Test. Tohn discovered a BRCA1 variant shared with her father and chose preventive surgeries after learning her elevated breast and ovarian cancer risks.
The MyRisk test with RiskScore evaluates 63 genes across 11 cancer types, using personal history, family history, and ~150 genetic markers to estimate five-year and lifetime breast cancer risk. Testing uses blood or saliva, typically returns results within 14 days, and includes access to board-certified genetic counselors.
Myriad Genetics (NASDAQ: MYGN) said management will attend two investor healthcare conferences in May and June 2026.
Executives will hold 1-to-1 investor meetings at the BofA Securities 2026 Health Care Conference on May 13, 2026, and a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a live audio webcast available on the investor site.
Myriad Genetics (NASDAQ: MYGN) reported Q1 2026 revenue of $200.4 million, up 2% year‑over‑year, with gross margin at 68.7%. GAAP net loss was $34.1 million and adjusted EBITDA was $(4.5) million. The company reiterated full‑year 2026 guidance of $860–$880 million revenue and adjusted EBITDA of $37–$49 million. Key operational highlights include a 13% cancer care volume increase, a 15% decline in prenatal revenue, FDA approval of MyChoice CDx as companion diagnostic for Zejula, and the launch of Precise MRD.
Myriad Genetics (NASDAQ: MYGN) released the GeneSight Mental Health Monitor national survey on April 30, 2026. The survey finds patients with depression and/or anxiety report treatment feels "one-size-fits-all" and 88% would feel more confident with a personalized mental health care plan.
Other findings: 41% of medicated patients call treatment one-size-fits-all; 74% of those still finding a medication feel the same; 65% were unaware genetic testing could inform medication decisions.
Myriad Genetics (NASDAQ: MYGN) will release its first quarter 2026 financial results after market close on May 5, 2026, with a conference call and webcast at 4:30 p.m. ET the same day. Investors can join via live webcast on investor.myriad.com or by telephone after registration; an archived webcast will be available following the call.